In my continuing reports about interesting and pertinent information released at the ASCO 2014 meeting one abstract described a phase 2 trial combining an attack on androgens in metastatic prostate cancer resistant to initial hormone therapy. This proof of concept study showed that combining Enzalutamide (Xtandi) plus abiraterone (Zytiga) drove down testosterone levels and appeared safe.
They found that Enzalutamide (Xtandi) plus abiraterone (Zytiga) dropped blood and bone marrow androgens down to undetectable levels for 80% of men, reported by Eleni Efstathiou, MD, PhD, of the MD Anderson Cancer Center in Houston.
The trial looked at the Pharmacokinetics of the combination of these two new drugs and the results suggested no meaningful negative interactions for either drug on the other, suggesting both can be used at full d